Merck And Altimmune Vie To Be Leaders In NAFLD And NASH
Rivals Will Present At Next Week’s EASL Congress
While progress in NASH has been slow for years, two dual GLP-1/GR agonists from rivals Merck & Co and Altimmune are showing mid-stage promise.
While progress in NASH has been slow for years, two dual GLP-1/GR agonists from rivals Merck & Co and Altimmune are showing mid-stage promise.